Abi Pinchbeck, Editor,Cell & Gene Therapy Insights, speaks to Devyn Smith, CEO at Arbor Biotechnologies, about the company’s innovative work in gene editing technologies developed to surpass the limitations of traditional CRISPR/Cas9 methods in addition to its pioneering AI/ML approaches. They also discuss the direction of regulatory guidance for gene editing and the overall future of the field as the era of commercial genome editing-based therapeutics arrives.
